185 related articles for article (PubMed ID: 18626311)
1. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma.
Vihinen P; Koskivuo I; Syrjänen K; Tervahartiala T; Sorsa T; Pyrhönen S
Melanoma Res; 2008 Aug; 18(4):268-73. PubMed ID: 18626311
[TBL] [Abstract][Full Text] [Related]
2. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
3. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
[TBL] [Abstract][Full Text] [Related]
5. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
8. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 4. The relation of cross-sectional profile, level of invasion, ulceration and vascular invasion to tumour type and prognosis.
Larsen TE; Grude TH
Acta Pathol Microbiol Scand A; 1979 Mar; 87A(2):131-8. PubMed ID: 433595
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
[TBL] [Abstract][Full Text] [Related]
10. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography.
Kurschat P; Wickenhauser C; Groth W; Krieg T; Mauch C
J Pathol; 2002 Jun; 197(2):179-87. PubMed ID: 12015741
[TBL] [Abstract][Full Text] [Related]
11. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
13. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis.
Larsen TE; Grude TH
Acta Pathol Microbiol Scand A; 1978 Nov; 86A(6):523-30. PubMed ID: 716913
[TBL] [Abstract][Full Text] [Related]
14. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study.
Srivastava A; Laidler P; Davies RP; Horgan K; Hughes LE
Am J Pathol; 1988 Nov; 133(2):419-23. PubMed ID: 3189515
[TBL] [Abstract][Full Text] [Related]
16. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.
Vihinen PP; Hilli J; Vuoristo MS; Syrjänen KJ; Kähäri VM; Pyrhönen SO
Acta Oncol; 2007; 46(5):678-84. PubMed ID: 17562445
[TBL] [Abstract][Full Text] [Related]
17. Novel biomarkers in malignant melanoma.
Bosserhoff AK
Clin Chim Acta; 2006 May; 367(1-2):28-35. PubMed ID: 16480699
[TBL] [Abstract][Full Text] [Related]
18. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
[TBL] [Abstract][Full Text] [Related]
19. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
20. Tenascin-C in primary malignant melanoma of the skin.
Ilmonen S; Jahkola T; Turunen JP; Muhonen T; Asko-Seljavaara S
Histopathology; 2004 Oct; 45(4):405-11. PubMed ID: 15469480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
